These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 36572783)
21. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Chen N; Wen L; Lau H; Surapaneni S; Kumar G Cancer Chemother Pharmacol; 2012 Mar; 69(3):789-97. PubMed ID: 22037879 [TBL] [Abstract][Full Text] [Related]
22. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of absorption, distribution, metabolism, and excretion of [ Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, Disposition, and Biotransformation of [ Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562 [TBL] [Abstract][Full Text] [Related]
25. Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects. Zhang X; Fettner S; Winter E; Masjedizadeh M; Hisoire G Int J Clin Pharmacol Ther; 2011 Jun; 49(6):345-52. PubMed ID: 21612741 [TBL] [Abstract][Full Text] [Related]
26. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Stopfer P; Marzin K; Narjes H; Gansser D; Shahidi M; Uttereuther-Fischer M; Ebner T Cancer Chemother Pharmacol; 2012 Apr; 69(4):1051-61. PubMed ID: 22200729 [TBL] [Abstract][Full Text] [Related]
27. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237 [TBL] [Abstract][Full Text] [Related]
28. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Johnson TR; Tan W; Goulet L; Smith EB; Yamazaki S; Walker GS; O'Gorman MT; Bedarida G; Zou HY; Christensen JG; Nguyen LN; Shen Z; Dalvie D; Bello A; Smith BJ Xenobiotica; 2015 Jan; 45(1):45-59. PubMed ID: 25034009 [TBL] [Abstract][Full Text] [Related]
29. Absorption, metabolism and excretion of [ Vuu I; Dahal UP; Wang Z; Shen X; Rodgers J; Wahlstrom J; Houk B Cancer Chemother Pharmacol; 2022 Oct; 90(4):357-367. PubMed ID: 36063185 [TBL] [Abstract][Full Text] [Related]
30. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Hoffmann M; Kasserra C; Reyes J; Schafer P; Kosek J; Capone L; Parton A; Kim-Kang H; Surapaneni S; Kumar G Cancer Chemother Pharmacol; 2013 Feb; 71(2):489-501. PubMed ID: 23203815 [TBL] [Abstract][Full Text] [Related]
31. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002 [TBL] [Abstract][Full Text] [Related]
32. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers. Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600 [TBL] [Abstract][Full Text] [Related]
33. Disposition of a low dose of 14C-bisphenol A in male rats and its main biliary excretion as BPA glucuronide. Kurebayashi H; Betsui H; Ohno Y Toxicol Sci; 2003 May; 73(1):17-25. PubMed ID: 12700409 [TBL] [Abstract][Full Text] [Related]
34. Metabolism, excretion and pharmacokinetics of [ Lam JL; Vaz A; Hee B; Liang Y; Yang X; Shaik MN Xenobiotica; 2017 Dec; 47(12):1064-1076. PubMed ID: 27866461 [TBL] [Abstract][Full Text] [Related]
35. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Hoffmann M; Kumar G; Schafer P; Cedzik D; Capone L; Fong KL; Gu Z; Heller D; Feng H; Surapaneni S; Laskin O; Wu A Xenobiotica; 2011 Dec; 41(12):1063-75. PubMed ID: 21859393 [TBL] [Abstract][Full Text] [Related]
36. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322 [TBL] [Abstract][Full Text] [Related]
37. Absorption, Metabolism, and Excretion of [ Xie L; Xu Y; Liu W; Zhou C; Guo L; Zhou S; Zhang C; Chen J; Zhu B; Ding S; Li H; Zhang L; Wang L; Xu L; Shao F; Wang L Clin Pharmacol Drug Dev; 2024 Oct; 13(10):1115-1122. PubMed ID: 39101494 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans. Xu D; Divanji P; Griffith A; Sukhun R; Cheplo K; Li J; German P Pharmacol Res Perspect; 2024 Oct; 12(5):e70006. PubMed ID: 39257068 [TBL] [Abstract][Full Text] [Related]
39. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [ Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928 [TBL] [Abstract][Full Text] [Related]
40. Absorption, metabolism, and excretion of [ Ye YE; Woodward CN; Narasimhan NI Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]